Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
NCT06445114
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Oropharyngeal Cancer
Carcinoma
Interventions
DRUG:
Cisplatin
Sponsor
Zachary Zumsteg